Antibody Solutions

Antibody Solutions is a privately held American biotechnology services company and contract research organization headquartered in Santa Clara, California. It supports biopharmaceutical companies, diagnostic developers, and academic researchers with antibody discovery, characterization, engineering, production, and analytical programs. Its work spans early research and discovery through fit-for-purpose reagent development, pharmacokinetic and immunogenicity testing, ligand-binding assays, potency analysis, and other services used in therapeutic and diagnostic development. The company was founded in 1995 by John Kenney, Judith Lynch-Kenney, Dennis Gould, and Bette Gould. Kenney had previously managed the monoclonal-antibody development laboratory at Syntex Research, which was associated with Roche, while Gould had managed a monoclonal-antibody production facility at Syva Diagnostics. The founders established Antibody Solutions during an early period in the growth of independent antibody-discovery providers, with an initial emphasis on custom antibody discovery for therapeutic, diagnostic, and critical-reagent applications. The company was incorporated in 1998, with Kenney serving as president and Lynch-Kenney as chief financial officer. Antibody Solutions developed a reputation around custom and specialized antibody programs rather than a mass-market branded product portfolio. Its capabilities include monoclonal and polyclonal antibody development, antigen design and preparation, molecular modeling, antibody sequencing, antibody engineering, anti-idiotype antibody generation, peptide synthesis, bioreactor-based production, and support for difficult targets such as membrane proteins. The company also works on antibodies and assays associated with pharmacokinetics, anti-drug antibodies, immunogenicity, drug potency, and ligand binding. Its services can include project management and technical coordination across multiple stages of a research program. A notable technology milestone came in 2000, when the company became the first contract research organization to produce antibodies in CELLine flasks, a bioreactor format used for antibody production and research workflows. Over time, Antibody Solutions also entered strategic relationships with technology and platform companies including Open Monoclonal Technology, Reflexion Pharmaceuticals, Guava Technologies, Single-Cell Technologies, Trianni, Harbour Antibodies, OmniAb, and Alloy Therapeutics. These relationships expanded the range of animal, single-cell, recombinant-expression, and discovery-platform approaches available to its clients. The company has conducted and presented independent research involving human monoclonal-antibody discovery, transgenic-animal platforms, single B-cell approaches, molecular-modeling-assisted discovery, difficult membrane targets, therapeutic antibody validation, and assay development. Examples include work involving the OmniAb platform, OmniRat and H2L2 mouse systems, Alloy Therapeutics mice, vascular endothelial growth factors, immune-checkpoint targets, cystine-knot fusion proteins, and assays for obiltoxaximab in the presence of anthrax protective antigen. Antibody Solutions operated in Mountain View from 2004 through 2011 before moving to facilities in Sunnyvale. In 2019 it relocated to a 33,300-square-foot facility on Scott Boulevard in Santa Clara. A facility grand opening held on January 30, 2020, coincided with the company's 25th anniversary. The business remains positioned as a specialized research-services partner for organizations that need custom antibodies, discovery support, assay development, or analytical services without building all of those capabilities internally.

Antibody Solutions was established in 1995 by John Kenney, Judith Lynch-Kenney, Dennis Gould, and Bette Gould. The founders brought experience from established life-science organizations: Kenney had led a monoclonal-antibody development laboratory at Syntex Research, while Gould had managed monoclonal-antibody production at Syva Diagnostics. Barry Bredt assisted the startup by securing the antibody.com domain name. Bredt later became associated with the University of California, San Francisco General Clinical Research Center and was known for work related to HIV/AIDS diagnostics; he died in 2007. The company was incorporated in 1998. Kenney became president and Judith Lynch-Kenney became chief financial officer. From the outset, Antibody Solutions concentrated on custom antibody discovery for therapeutic, diagnostic, and critical-reagent uses. This positioned the company among the early independent providers of antibody discovery services, at a time when biotechnology companies increasingly outsourced specialized research activities. In 2000, Antibody Solutions adopted CELLine flask bioreactor technology for antibody production and became the first contract research organization reported to use that system for antibody production. The company subsequently broadened its technical capabilities to include monoclonal and polyclonal antibody development, molecular modeling, antibody sequencing, antibody engineering, peptide synthesis, pharmacokinetic studies, immunoassay development, ligand-binding analysis, and drug potency testing. It also developed services for challenging biological targets, including difficult membrane proteins, and supported CAR-T and other advanced therapeutic research. From 2004 to 2011, the company was headquartered in Mountain View, California. It moved to Sunnyvale in 2011 and later relocated to a 33,300-square-foot facility at 3033 Scott Boulevard in Santa Clara in mid-2019. The new location was formally opened on January 30, 2020, in an event associated with the company's 25th anniversary. During its development, Antibody Solutions formed strategic agreements or working relationships with a range of life-science technology companies. The organizations named in reference material include Open Monoclonal Technology, Reflexion Pharmaceuticals, Guava Technologies, Single-Cell Technologies, Trianni, Harbour Antibodies, OmniAb, and Alloy Therapeutics. These relationships gave the company access to, or experience with, transgenic-animal, recombinant, single-cell, and other antibody-discovery approaches. The company has also generated independent research presented in publications and scientific forums. Its research topics include human monoclonal antibodies from transgenic animals, molecular-modeling-guided discovery, single B-cell discovery, antibodies against difficult membrane proteins, immune-checkpoint targets, vascular endothelial growth factors, and development of pharmacokinetic, anti-drug-antibody, immunogenicity, and potency assays. Antibody Solutions continues to operate as a specialized contract research and development services provider rather than as a consumer-facing pharmaceutical brand.

1. 2020Santa Clara facility grand opening

   A grand opening for the Scott Boulevard facility took place on January 30, coinciding with the company's 25th anniversary.

   Source
2. 2019Relocation to Santa Clara facility

   Antibody Solutions moved to a 33,300-square-foot facility on Scott Boulevard in Santa Clara.

   Source
3. 2011Move to Sunnyvale

   The company moved its headquarters and operations from Mountain View to Sunnyvale.

   Source
4. 2004Mountain View headquarters period begins

   Antibody Solutions was headquartered in Mountain View, California, during a period of expansion in its antibody research services.

   Source
5. 2000CELLine bioreactor milestone

   The company became the first contract research organization reported to produce antibodies in CELLine flasks.

   Source
6. 1998Incorporation

   Antibody Solutions was incorporated, with John Kenney serving as president and Judith Lynch-Kenney serving as chief financial officer.

   Source
7. 1995Company founded

   John Kenney, Judith Lynch-Kenney, Dennis Gould, and Bette Gould founded Antibody Solutions as an independent antibody discovery services company.

   Source

A specialized, technology-oriented antibody contract research organization serving biopharmaceutical, diagnostic, and academic customers with integrated discovery, development, engineering, production, and assay capabilities.

• Therapeutic antibody discoveryBiotechnology research service

  Discovery programs for therapeutic antibodies, including generation and selection of monoclonal antibodies from animal, recombinant, and single-cell platforms. The work can cover difficult targets, immune-checkpoint targets, membrane proteins, and other biologically important antigens.

• Monoclonal and polyclonal antibody developmentAntibody development service1995

  Custom development of monoclonal and polyclonal antibodies for therapeutic research, diagnostics, assay development, and critical-reagent applications. Programs may include antigen preparation, immunization, screening, characterization, and production support.

• Antibody engineering and sequencingBiotechnology research service

  Sequencing and engineering services used to characterize antibody molecules and improve their suitability for research or development. Related work includes molecular modeling, recombinant expression, and support for therapeutic antibody discovery.

• Pharmacokinetic and immunogenicity assaysBioanalytical service

  Development and analysis of assays for pharmacokinetic measurements, anti-drug antibodies, immunogenicity, and related reagent or control systems. These services support characterization of biologic candidates and interpretation of preclinical or clinical research data.

• Immunoassay and ligand-binding assay developmentAssay development service

  Development, optimization, and analysis of immunoassays and ligand-binding assays for biologics, diagnostic research, and other laboratory applications. The company also provides drug potency assay analysis and related technical support.

• Research-grade and fit-for-purpose antibodiesResearch reagent

  Fit-for-purpose antibodies and related reagents supplied for biopharmaceutical, diagnostic, and academic research. The offering can include anti-protein antibodies, anti-idiotype antibodies, in vivo study-grade materials, and reagents for analytical assays.

• 2019Relocation to a larger Santa Clara facilityStrategy

  The company had previously operated in Mountain View and Sunnyvale and required a dedicated facility for its continuing research and service activities.

  What changed. Antibody Solutions moved to a 33,300-square-foot facility at 3033 Scott Boulevard in Santa Clara.

  Aftermath. The facility was formally opened in January 2020 and became the company's stated headquarters.

  Source
• 2000Adoption of CELLine flask bioreactor technologyStrategy

  Antibody Solutions was expanding its antibody production and contract research capabilities during an early phase of independent antibody-service growth.

  What changed. The company adopted CELLine flask bioreactors and became the first contract research organization reported to produce antibodies using the technology.

  Aftermath. The move reinforced the company's emphasis on specialized antibody production and technology-enabled research services.

  Source

1. Antibody Solutions